

GrowX Global Appoints Dr. Ragina Naidu, Ph.D as Chief Scientist

Vancouver, British Columbia, August 23, 2019 - [GrowX Global Corp](#) ("GrowX"), a producer and exporter of Cannabis and Hemp products based in Vancouver B.C., is pleased to announce that it has appointed Dr. Ragina Naidu, Ph.D as Chief Scientist, Quality Assurance and Research and Development.

Dr. Naidu's 20 years of experience in the biopharmaceutical industry creates immediate value for GrowX. Dr. Naidu holds a PhD in Synthetic Organic Chemistry from Australian National University and has worked in various research and development (R&D) and production capacities. As such, she is highly regarded for her innovative ability to develop, adopt and adapt different technologies in pharmaceutical development from proof-of-concept to manufacturing at scale.

Furthermore, Dr. Naidu's in-depth experience in Health Canada's regulatory processes will be valuable as we navigate the ever-changing cannabis landscape. Dr. Naidu joins GrowX from BN Pharmaceuticals Inc/Chatham Biotec Ltd where she was Chief Scientific Officer. Dr. Naidu was responsible for the development and manufacturing of drug substances and drug products in accordance with applicable industry and government quality and regulatory standards.

In addition to leading the Quality and Regulatory Compliance team, Dr. Naidu will utilize her scientific expertise to help set up a state-of-the-art Cannabis testing lab and extraction facility at GrowX.

An accomplished anti-cancer drug scientist, Dr. Naidu holds numerous patents and has produced Drug Master Files (DMF) for the US Food and Drug Administration (FDA).

For more information about Dr. Naidu or general information about GrowX Global, please contact us at info@growxglobal.com

About GrowX Global Corp.

GrowX Global is positioned to be a Canadian producer and exporter of dry cannabis, cannabis oils and hemp products. We are focused on bridging the gap between the current global lack of supply and massive growing demand for Hemp based CBD and pharmaceutical grade Cannabis products.

Contacts

Jas Basi, Chief Executive Officer
604-825-8714
jbasi@growxglobal.com

Neil Lock, VP of Capital Markets
604-380-4888
nlock@growxglobal.com

10708 Farms Rd., Mission, B.C., Canada V2V 4J1
Toll-free (877) 681-3120

Forward Looking Statements

This Newsletter contains certain information that may constitute “forward-looking information” within the meaning of Canadian securities laws and forward-looking statements within the meaning of U.S. federal securities laws, both of which the Corporation refers to as forward-looking information. Forward-looking information can be identified by the use of terms such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “intend”, “estimate”, “predict”, “potential”, “continue” or other similar expressions concerning matters that are not statements about the present or historical facts. Forward-looking information in this Newsletter includes, but is not limited to, information or statements about: the business model and illustrations; the Company’s strategy, future operations, prospects and the plans of management; the design, regulatory plan, timeline, costs and results of cannabis licensing and production; the timing of future meetings and discussions with Health Canada and other regulatory bodies; planned regulatory filings, and the timing thereof; anticipated marketing advantages and product differentiation of and its potential to become a licensed producer; the Company’s estimates of the size of the potential market, potential for market expansion, and the rate and degree of market acceptance, and the Company’s ability to serve such market; the Company’s strategy and ability to develop, commercialize and distribute in international markets; the Company’s ability to complete business development, marketing and other commercialization activities and the estimated timing thereof; the Corporation’s sales, distribution and marketing strategy; the Corporation’s intention and ability to obtain and maintain regulatory approvals, the timing and costs of obtaining same; the success of competing products that are or become available; the potential for commercial opportunities in various geographies and indications, including co-development and/or marketing partnerships and possible licensing and partnership opportunities, and the benefits to be derived from such commercial opportunities; and the Company’s preferred strategy to commercialize through strategic partnerships.

Although the forward-looking information in this Newsletter is based upon what the Company believes are reasonable assumptions, no person should place undue reliance on such information since actual results may vary materially from the forward-looking information. In addition, forward-looking information in this Newsletter is subject to a number of known and unknown risks, uncertainties and other factors, many of which are beyond the Company’s control, that could cause the Company’s actual results and developments to differ materially from those that are disclosed in or implied by the forward-looking information. Consequently, all the forward-looking information in this Newsletter is qualified by this cautionary statement and there can be no guarantee that the results or developments that the Company anticipates will be realized or, even if substantially realized, that they will have the expected consequences or effects on the Company’s business, financial condition or results of operations. Accordingly, you should not place undue reliance on the forward-looking information. Except as required by applicable law, the Company does not undertake to update or amend any forward-looking information, whether as a result of new information, future events or otherwise. All forward-looking information is made as of the date of this Newsletter.